Emerging concepts and recent advances in basal cell carcinoma [version 1; referees: 2 approved]

F1000Research

David Leffell¹  Mariam Totonchy² 

[1] Department of Dermatology, Section of Cutaneous Oncology and Dermatologic Surgery , Yale University School of Medicine, 40 Temple Street 5A, New Haven, Connecticut, USA;Department of Dermatology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208059, New Haven, CT 06520-8059, Connecticut, USA;

关键词: Cancer Therapeutics;    Dermatologic & Cosmetic Surgery;    Epidemiology;    Health Systems & Services Research;    Immunopharmacology & Hematologic Pharmacology;    Medical Genetics;    Skin Cancers (incl. Melanoma & Lymphoma);   

DOI  :  10.12688/f1000research.11314.1

来源: DOAJ

【 摘 要 】

Basal cell carcinoma (BCC) is the most common malignancy worldwide, arising from non-keratinizing cells within the basal layer of the epidermis. The incidence of BCC continues to rise annually, increasing the burden of management of these carcinomas and the morbidity associated with their treatment. While surgical interventions such as Mohs micrographic surgery and surgical excision are the standard of care and yield the highest cure rates, the number of non-surgical interventions approved for the treatment of BCC continues to expand. We review various surgical and non-surgical approaches to the treatment of BCC, focusing on targeted molecular therapies that are approved for locally advanced or recurrent disease.

【 授权许可】

Unknown